Navigation Links
Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement
Date:6/5/2008

ATLANTA, June 5 /PRNewswire/ -- Elekta, a world class leader in advanced radiation therapy and radiosurgery, has been selected to supply multiple Elekta Synergy(R) digital linear accelerator systems to Mary Bird Perkins Cancer Center over the next few years.

The new Elekta Synergy systems will provide expanded capacity for advanced Image Guided Radiation Therapy (IGRT), which Mary Bird Perkins (MBP) began providing to patients four years ago. The new systems will provide for MBP's current locations as well as the organization's long-term regional growth into new markets. MBP has locations in Baton Rouge, Hammond and Covington and is building a fourth location in Gonzales, LA.

Each of the estimated nine new treatment systems will include 3D X-ray Volume Imaging (XVI) and some will include ElektaVMAT Volumetric intensity Modulated Arc Therapy, enhancing MBP's Intensity Modulated Radiation Therapy (IMRT) and IGRT arsenal.

"We feel that Elekta is 'first class in its field' and provides dynamic, practical and reliable treatment options," said Todd D. Stevens, President and CEO, MBP. Every cancer case is unique and personal, and Mary Bird Perkins makes sure that it has the best radiation therapy options available to our treatment team so every cancer patient has individualized, optimal treatment."

The Center will be treating all types of cancer with the Elekta Synergy systems, from simple to the most complex cases. Elekta Synergy is a fully-digital linear accelerator with an integrated 3D imaging system that simultaneously acquires and reconstructs image data on the target and surrounding critical structures as a whole volume in a single gantry sweep. Because imaging occurs at the time of treatment, uncertainties due to organ motion or deformation and slight differences in patient set-up can be eliminated.

In its search for the best solution for patient care, Mary Bird Perkins diligently analyzed all proposals and mobilized a team of expert physicians, medical physicists, dosimetrists and radiation therapists to thoroughly research and review all options. "Elekta won a very competitive award, and we chose them because they offered a better solution for our patients," said Dr. Kenneth Hogstrom, chief of physics, MBP.

Joseph K. Jachinowski, President and CEO of Elekta North America stated: "We are extremely pleased to be able to supply our treatment delivery devices to Mary Bird Perkins. They have been a long time user of our Electronic Medical Record (EMR) system and the combination of adding Elekta Synergy treatment systems with the EMR will further enhance the integration of the delivery of cancer care benefiting patients across Mary Bird Perkins' network of facilities."

VMAT with Elekta Synergy

MBP makes it a priority to always be a pioneering user of new technologies that will improve patient outcomes. Elekta Synergy will enable the institution to implement Elekta VMAT* (Volumetric intensity Modulated Arc Therapy). This major advancement in radiation therapy surpasses traditional IMRT techniques by dramatically decreasing treatment times and providing highly conformal radiation dose distributions.

"In many cases, we feel Elekta VMAT will allow us to produce plans that are superior to those using conventional gantry-static IMRT deliveries," says Dr. John Gibbons, chief of clinical physics, MBP. "We look forward to helping Elekta deploy the application of VMAT technology for the benefit of cancer patients in Louisiana."

Elekta's VMAT solution will vary the monitor units (MU) per degree and beam intensities "on the fly" by simultaneously manipulating gantry position and speed, MLC leaves, dose rate, collimator angle and back-up diaphragms, all while the treatment beam is on. Additionally, where IMRT plans consist of several fields, or control points, the VMAT technique effectively has an unlimited number of fields.

Elekta believes VMAT's shorter treatment times translate into increased patient comfort by reducing time spent during treatment.

The Center also is using all available aspects of the MOSAIQ(R) image- enabled oncology electronic medical record (EMR) system. MOSAIQ supports and streamlines the entire cancer care work.ow process, from initial diagnosis and staging through scheduling, planning, treatment, billing and subsequent follow-up.

*Elekta VMAT is pending FDA 510(k) pre-market clearance and is not yet available for commercial delivery in the US.

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state-of-the-art tools to fight serious disease.

Elekta provides advanced clinical solutions and comprehensive management and information systems, as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in more than 5,000 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) for stereotactic radiosurgery or radiotherapy of the spine and body and Elekta Synergy(R) for advanced intensity modulated and image guided radiation therapy, as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With more than 2,500 employees globally, Elekta corporate headquarters are located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb.


'/>"/>
SOURCE Elekta Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Xoft Signs Sales Development Agreement With Elekta
2. Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages
3. Breathe Technologies, Inc. Closes on $15 Million in Venture Funding Led by Kleiner Perkins Caufield & Byers
4. Emageon Names Chris E. Perkins as Chief Operating Officer
5. Kylies breast cancer triggered a surge of over 30 percent in breast imaging of low-risk women
6. Synthetic molecules hold promise for new family of anti-cancer drugs
7. Insights into cancer earn Premiers Award Commendation
8. Take a Swing Against Breast Cancer!
9. Family history of colorectal cancer linked with reduced risk of cancer recurrence
10. Androgen Production Continues in Prostate Cancer Tumors
11. Family History Might Improve Odds Against Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... ... 2017 , ... New Jersey ranks among the top five states in the ... need for advanced services is growing. , Project WE vs C is a ... with their non-profit partners in their fight against cancer and in support of their ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is linked ... LRRK2 mutation, according to a study released today at the 1st Pan American ... link between pesticides and incidence of sporadic PD through occupational exposure. This latest ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully ... tests and pathology services, announced today the acceptance of ... United States and Canadian Academy of ... San Antonio, Texas . ... the Company,s extensive experience in molecular thyroid testing, including ...
(Date:2/27/2017)... CAESAREA , Israel and TAMPA, Fla. ... Heart Ltd., an emerging medical device company focused ... undergoing cardiac procedures, applauds the members of the ... past week for their acknowledgement of the need ... (TAVR) surgery. "The statements shared by ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology: